Extracellular vesicles are heterogeneous populations of secreted entities categorized primarily into exosomes, microvesicles, and apoptotic bodies, each differing in size, biogenesis pathways, and molecular contents. Exosomes, typically 30-150 nm in diameter, originate from the endosomal system through inward budding of multivesicular bodies, subsequently fusing with the plasma membrane to release their cargo. Microvesicles, larger vesicles ranging up to 1,000 nm, shed directly from the plasma membrane. Understanding the precise cellular machinery orchestrating the formation and release of these vesicles is not merely an academic pursuit but a cornerstone to deciphering how cancer cells exploit EVs to manipulate their microenvironment.

Cancer cells use EVs as efficient vehicles to transfer oncogenic molecules such as proteins, lipids, mRNAs, microRNAs, and even DNA fragments to neighboring cells and distant organs. This intercellular communication mediated by EVs reprograms recipient cells, promoting tumor growth, immune evasion, angiogenesis, and metastasis. The review presents compelling evidence that EV cargo composition is dynamically modulated by the cell’s pathological state, creating a snapshot of the tumor’s molecular landscape. This selective packaging mechanism is orchestrated by various pathways, including ESCRT (endosomal sorting complex required for transport) dependent and independent mechanisms, which highlight the regulatory complexity underlying EV biogenesis.

Of particular note is the role of EVs in enabling metastatic dissemination, a primary cause of cancer mortality. Tumor-derived EVs precondition distant sites—often referred to as forming a pre-metastatic niche—by remodeling stromal and immune components to be more permissive to metastatic colonization. The cargo transported by EVs orchestrates extracellular matrix remodeling, recruitment of immunosuppressive cells, and angiogenic signaling, collectively facilitating tumor cell seeding. This insight into EV-mediated interorgan communication redefines metastasis as a multi-step process heavily reliant on vesicle trafficking, rather than solely on cell-intrinsic motility and invasion.

From a diagnostic perspective, the review emphasizes the burgeoning interest in exploiting EVs as liquid biopsy tools. Their stability in biofluids such as blood, urine, and saliva, coupled with their tumor-specific molecular signatures, positions EVs as superior candidates for non-invasive early detection, prognostic assessments, and monitoring therapeutic responses. Advanced isolation techniques and high-throughput molecular profiling technologies now enable detailed characterization of EV populations, revealing biomarker panels with remarkable sensitivity and specificity. This promises to revolutionize cancer diagnostics, particularly in malignancies currently lacking reliable screening methods.

Therapeutically, EVs offer tantalizing opportunities both as targets and delivery vehicles. Targeting EV biogenesis, release, or uptake pathways provides a novel avenue to interrupt tumor-promoting intercellular communication, potentially sensitizing tumors to conventional therapies. Conversely, engineering EVs to serve as precision delivery systems for anti-cancer drugs, nucleic acids, or immunomodulatory molecules exploits their natural biocompatibility and homing abilities. The review highlights state-of-the-art approaches in harnessing EVs for targeted therapy, including modifications to enhance tumor specificity and cargo loading efficiency, heralding a new era of personalized cancer treatment modalities.

Underlying these advancements is an expanding repertoire of cutting-edge technologies. Novel imaging techniques such as super-resolution microscopy and cryo-electron microscopy now visualize EV dynamics and structural composition with unparalleled detail. Complementary omics analyses—proteomics, transcriptomics, lipidomics—provide comprehensive insights into EV content and functional implications. Computational modeling integrated with experimental data elucidates vesicle trafficking networks and predicts therapeutic outcomes. This multidisciplinary synergy propels EV research from descriptive biology toward actionable clinical applications.

Despite the transformative potential, challenges remain. Standardization of EV isolation and characterization protocols is imperative to ensure reproducibility and comparability across studies. Heterogeneity within and between EV populations complicates the interpretation of functional roles and biomarker efficacy. Additionally, translating experimental findings into safe and efficacious clinical interventions demands rigorous validation and regulatory oversight. The review candidly discusses these limitations, advocating sustained collaborative efforts to overcome technical hurdles and ethical considerations.

The emerging narrative positions extracellular vesicles not merely as cellular byproducts but as central agents in cancer pathophysiology, diagnostics, and therapeutics. By shedding light on the molecular intricacies of EV biogenesis and cargo selection, and by elucidating their diverse oncogenic mechanisms, this body of work charts a path forward for innovative clinical strategies. Harnessing the full potential of EV biology could dramatically improve patient outcomes by enabling earlier detection, more precise monitoring, and tailored interventions.

In the broader oncology landscape, EV-based research is emblematic of a shift toward understanding cancer as a systemic disease involving complex intercellular communications rather than isolated aberrant cells. This holistic viewpoint is critical as it opens avenues not only for directly targeting tumor cells but also modulating the tumor microenvironment and systemic host responses. The interface of EV biology with immuno-oncology, for instance, is a particularly fertile area, with investigations into EV-mediated immune modulation informing novel immunotherapeutic designs.

Moreover, the scalability and versatility of EVs as therapeutics are advantageous for future clinical translation. Unlike synthetic nanoparticles, their endogenous origin confers superior biocompatibility and immune evasion capabilities. Adaptation of EVs for delivery of CRISPR-Cas systems, small interfering RNAs, or chemotherapeutic agents offers a platform adaptable to multiple cancer types and genetic contexts, addressing the inherent heterogeneity of malignancies.

Looking ahead, research is anticipated to delve deeper into the molecular determinants governing EV cargo specificity and destination targeting. Pinpointing key regulatory molecules will enable refined modulation of EV functions, either augmenting beneficial effects or blocking detrimental influences. Integrating EV studies with patient-derived organoids and in vivo models will facilitate precision medicine approaches tailored to individual tumor EV profiles.

In conclusion, the exhaustive analysis presented by Aditi and colleagues crystallizes the critical importance of extracellular vesicles in cancer biology and clinical oncology. This burgeoning field stands at the intersection of molecular cell biology, translational research, and therapeutic innovation. As we harness the intricate language of EV-mediated intercellular communication, we edge closer to breakthroughs that could transform cancer management, offering hope for more effective, less invasive, and personalized treatments. The journey from bench to bedside is underway, fueled by these diminutive yet powerful vesicles that carry the whispers and commands of cancer cells in their molecular cargo.

Subject of Research: Extracellular vesicles in cancer, including their formation, roles in oncogenesis, potential as biomarkers, and therapeutic applications.

Article Title: Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications.

Article References:
Aditi, Khajuria, A., Garima et al. Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications. Med Oncol 43, 23 (2026). https://doi.org/10.1007/s12032-025-03145-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03145-x

The overarching theme of the conference, “Bridging Two Frontiers: Mitochondria & Microbiota,” reflects a paradigm shift in how we perceive cellular crosstalk and systemic homeostasis. Extracellular vesicles serve as critical conduits linking mitochondrial function—a central hub of cellular energy metabolism and apoptotic regulation—with the expansive and diverse human microbiota ecosystem that governs immune responses, nutrient metabolism, and overall health. Integrating these domains offers unprecedented opportunities for developing novel diagnostic biomarkers and targeted therapeutic interventions, which could revolutionize personalized medicine.

Keynote lectures will underscore the emerging mechanistic insights into EV biogenesis, a complex and tightly regulated process that involves the maturation of endosomal compartments and plasma membrane budding. Understanding the molecular underpinnings of EV formation is crucial, as it governs their cargo specificity and ultimately their biological functions. Sessions will delve into the latest advances in EV isolation and purification techniques, emphasizing scalable methods such as size-exclusion chromatography, ultracentrifugation, and affinity-based capture—all vital for ensuring the reproducibility and translational validity of EV-based research.

Therapeutic development remains at the heart of this congress, with presentations highlighting innovative strategies that utilize EVs as vehicles for drug delivery and regenerative therapies. Leveraging the inherent biocompatibility and tissue-targeting capabilities of EVs, researchers are engineering vesicles loaded with nucleic acids, proteins, or small molecules aimed at modulating mitochondrial dysfunction or microbial dysbiosis—two pathological hallmarks underpinning a broad spectrum of diseases including neurodegeneration, metabolic syndromes, and cancers.

Another facet of the congress will showcase cutting-edge technologies that augment the characterization and application of EVs. High-resolution flow cytometry, nanoparticle tracking analysis, and advanced imaging modalities enable precise phenotyping and functional assays of vesicle populations, paving the way for standardization across laboratories. Furthermore, novel platforms for EV engineering and delivery will be spotlighted, featuring synthetic biology approaches and nanomaterial conjugation to enhance targeting efficacy and payload stability.

The intersection of mitochondria and microbiota through EV-mediated pathways also opens fresh investigative avenues concerning host-microbe communication. Emerging evidence delineates how mitochondrial-derived vesicles influence microbial communities and, conversely, how microbiota-derived EVs impact mitochondrial dynamics. This bidirectional dialogue is pivotal in maintaining systemic homeostasis and offers promising therapeutic targets across immune-mediated and metabolic diseases.

Conference chairs Dr. Consuelo Borrás and Dr. Marvin Edeas emphasize the significance of multidisciplinary collaboration in accelerating breakthroughs. By convening experts from the realms of molecular biology, microbiology, clinical sciences, and bioengineering, the event aims to catalyze innovative dialogue and foster integrative approaches that transcend traditional research silos.

Attendees will have the opportunity to engage with a diverse array of formats including oral presentations, poster sessions, and technology showcases. There is an open call for abstracts and innovation proposals, encouraging contributions that span foundational biology to translational applications. Contributions highlighting the molecular characterization of EV cargo, their roles in mitochondrial homeostasis, or the modulation of microbial ecosystems through EVs are highly sought.

Crucially, the congress also intends to address existing challenges in EV research, such as nomenclature standardization, vesicle heterogeneity, and intravesicular cargo variability. By embracing these complexities, the scientific community hopes to establish consensus guidelines and foster reproducibility, which are imperative for clinical deployment.

The event’s timing could not be more opportune, as EV research is rapidly maturing from a niche focus area into a robust translational discipline with tangible clinical implications. Innovations born out of this congress are expected to influence diverse fields ranging from oncology and neurology to infectious diseases and metabolic disorders.

Researchers, clinicians, and industry leaders alike are encouraged to leverage this unique platform to propel EV science forward. The exchange of ideas within this congress will undoubtedly spur novel hypotheses, collaborative projects, and next-generation diagnostic and therapeutic technologies.

Abstract submissions are welcomed until September 10, 2025, and additional information can be found via the World Mitochondria Society and International Society of Microbiota’s official channels. Together, these organizations underscore their commitment to advancing science at the convergence of basic biology, clinical research, and translational innovation. Through this congress, they aim to unveil new horizons in medicine by harnessing the power of extracellular vesicles.

Subject of Research: Extracellular vesicles in mitochondrial and microbiota communication, with a focus on diagnostics, targeted drug delivery, and regenerative medicine.

Article Title: Second World Congress on Targeting Extracellular Vesicles Bridges Mitochondrial and Microbiota Frontiers

News Publication Date: Not specified (event scheduled for October 15-16, 2025)

Image Credits: Credit: Second World Congress on Targeting EVs

Keywords: Exosomes, Vesicles, Mitochondrial function, Mitochondrial DNA, Mitochondrial biogenesis, Human microbiota, Microbiota